Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

被引:0
|
作者
Tomonori Minagawa
Yasushi Murata
Shinichiro Uchikawa
Takeshi Uehara
机构
[1] Azumino Red Cross Hospital,Department of Urology
[2] Azumino Red Cross Hospital,Department of Cardiovascular Medicine
[3] Shinshu University School of Medicine,Department of Laboratory Medicine
关键词
Prostate cancer; Pericardial metastasis; Prostate-specific antigen;
D O I
暂无
中图分类号
学科分类号
摘要
An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea. At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml. Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion. Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells. It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma. However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer. After drainage and intrapericardial injection of cisplatin, the amount of effusion was decreased. After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
引用
收藏
页码:101 / 103
页数:2
相关论文
共 50 条
  • [21] Therapeutic options for hormone-refractory prostate cancer
    Miller, K.
    Boergermann, C.
    Thueroff, J.
    Albers, P.
    Wirth, M.
    UROLOGE, 2006, 45 (05): : 580 - +
  • [22] Paclitaxel in the treatment of hormone-refractory prostate cancer
    Smith, DC
    Pienta, KJ
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 109 - 111
  • [23] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [24] Hormone-refractory prostate cancer: Therapeutic approach
    Pepe, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Calabria, C.
    Laudani, A.
    Usset, A.
    Cusimano, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 155
  • [25] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [26] The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Pierre Karakiewicz
    Paul Perrotte
    World Journal of Urology, 2005, 23 : 14 - 18
  • [27] DocetaxelIn Hormone-Refractory Metastatic Prostate Cancer
    Kate McKeage
    Susan J. Keam
    Drugs, 2005, 65 : 2287 - 2294
  • [28] The role of endothelin in hormone-refractory prostate cancer
    Zonnenberg, BA
    Voest, EE
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 9 - 14
  • [29] Combination therapy in hormone-refractory prostate cancer
    Daniel P. Petrylak
    Current Oncology Reports, 2001, 3 (5) : 453 - 453
  • [30] Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
    Small, EJ
    Fippin, LJ
    Whisenant, SP
    CANCER INVESTIGATION, 1998, 16 (07) : 456 - 461